NADPH oxidases in vascular pathology

Antioxidants and Redox Signaling

Volumn 20, Issue 17, 2014, Pages 2794-2814

  Konior, Anna ^a   Schramm, Agata ^a   Czesnikiewicz Guzik, Marta ^a,b   Guzik, Tomasz J ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DUOX1 PROTEIN; DUOX2 PROTEIN; ENZYME INHIBITOR; NOX3 PROTEIN; NOX5 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; UNCLASSIFIED DRUG; ISOPROTEIN;

ADIPOCYTE; ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; FIBROBLAST; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PULMONARY HYPERTENSION; REVIEW; SEASONAL VARIATION; SMOOTH MUSCLE FIBER; STRESS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULARIZATION; VASCULITIS; ANIMAL; CLASSIFICATION; ENZYMOLOGY; GENETICS; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; RISK FACTOR; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; MUSCLE, SMOOTH, VASCULAR; NADPH OXIDASE; OXIDATIVE STRESS; PROTEIN ISOFORMS; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 84901020334     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5607     Document Type: Review

References (211)

1. Adachi Y, Shibai Y, Mitsushita J, Shang WH, Hirose K, and Kamata T. Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. Oncogene 27: 4921-4932, 2008
2. Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, and Brandes RP. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 279: 45935-45941, 2004
3. Anilkumar N, Jose GS, Sawyer I, Santos CX, Sand C, Brewer AC, Warren D, and Shah AM. A 28-kDa splice variant of NADPH oxidase-4 is nuclear-localized and involved in redox signaling in vascular cells. Arterioscler Thromb Vasc Biol 33: E104-e112, 2013
4. Anilkumar N, Weber R, Zhang M, Brewer A, and Shah AM. Nox4 and nox2 NADPH oxidases mediate distinct cellular redox signaling responses to agonist stimulation. Arterioscler Thromb Vasc Biol 28: 1347-1354, 2008
5. Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, Antonopoulos AS, Demosthenous M, Miliou A, Psarros C, Marinou K, Sfyras N, Economopoulos G, Casadei B, Channon KM, and Stefanadis C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPHoxidase activity. Circulation 122: S66-S73, 2010
6. Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS, and Lambeth JD. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A 99: 715-720, 2002
7. Banfi B, Maturana A, Jaconi S, Arnaudeau S, Laforge T, Sinha B, Ligeti E, Demaurex N, and Krause KH. A mammalian H+ channel generated through alternative splicing of the NADPH oxidase homolog NOH-1. Science 287: 138-142, 2000
8. Banfi B, Molnar G, Maturana A, Steger K, Hegedus B, Demaurex N, and Krause KH. A Ca(2 + )-Activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem 276: 37594-37601, 2001
9. Banfi B, Tirone F, Durussel I, Knisz J, Moskwa P, Molnar GZ, Krause KH, and Cox JA. Mechanism of Ca2 + activation of the NADPH oxidase 5 (NOX5). J Biol Chem 279: 18583-18591, 2004
10. Barry-Lane PA, Patterson C, van Der Merwe M, Hu Z, Holland SM, Yeh ET, and Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 108: 1513-1522, 2001
11. Basuroy S, Bhattacharya S, Leffler CW, and Parfenova H. Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-Alpha in cerebral vascular endothelial cells. Am J Physiol Cell Physiol 296: C422-C432, 2009
12. Bauldry SA, Elsey KL, and Bass DA. Activation of NADPH oxidase and phospholipase D in permeabilized human neutrophils. Correlation between oxidase activation and phosphatidic acid production. J Biol Chem 267: 25141-25152, 1992
13. Baumer AT, Kruger CA, Falkenberg J, Freyhaus HT, Rosen R, Fink K, and Rosenkranz S. The NAD(P)H oxidase inhibitor apocynin improves endothelial NO/superoxide balance and lowers effectively blood pressure in spontaneously hypertensive rats: Comparison to calcium channel blockade. Clin Exp Hypertens 29: 287-299, 2007
14. Bayraktutan U, Blayney L, and Shah AM. Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscler Thromb Vasc Biol 20: 1903-1911, 2000
15. Bedard K and Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev 87: 245-313, 2007
16. BelAiba RS, Djordjevic T, Petry A, Diemer K, Bonello S, Banfi B, Hess J, Pogrebniak A, Bickel C, and Gorlach A. NOX5 variants are functionally active in endothelial cells. Free Radic Biol Med 42: 446-459, 2007
17. Bendall JK, Cave AC, Heymes C, Gall N, and Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105: 293-296, 2002
18. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, and Dominiczak AF. Investigation into the sources of superoxide in human blood vessels: Angiotensin II increases superoxide production in human internal mammary arteries. Circulation 101: 2206-2212, 2000
19. Bokoch GM and Knaus UG. NADPH oxidases: Not just for leukocytes anymore! Trends Biochem Sci 28: 502-508, 2003
20. Borregaard N, Heiple JM, Simons ER, and Clark RA. Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: Translocation during activation. J Cell Biol 97: 52-61, 1983
21. Braga VA, Colombari E, and Jovita MG. Angiotensin II-derived reactive oxygen species underpinning the processing of the cardiovascular reflexes in the medulla oblongata. Neurosci Bull 27: 269-274, 2011
22. Brandes RP, Takac I, and Schroder K. No superoxide-no stress?: Nox4, the good NADPH oxidase! Arterioscler Thromb Vasc Biol 31: 1255-1257, 2011
23. Brandes RP, Viedt C, Nguyen K, Beer S, Kreuzer J, Busse R, and Gorlach A. Thrombin-induced MCP-1 expression involves activation of the p22phox-containing NADPH oxidase in human vascular smooth muscle cells. Thromb Haemost 85: 1104-1110, 2001
24. Braunersreuther V, Montecucco F, Ashri M, Pelli G, Galan K, Frias M, Burger F, Quinderé AL, Montessuit C, Krause KH, Mach F, and Jaquet V. Role of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in myocardial ischemia/ reperfusion injury. J Mol Cell Cardiol. 64: 99-107, 2013
25. Bush E, Maeda N, Kuziel WA, Dawson TC, Wilcox JN, DeLeon H, and Taylor WR. CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension. Hypertension 36: 360-363, 2000
26. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, and Shah AM. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin IIinduced cardiac hypertrophy. Circ Res 93: 802-805, 2003
27. Cai T, Fassina G, Morini M, Aluigi MG, Masiello L, Fontanini G, D'Agostini F, De Flora S, Noonan DM, and Albini A. N-Acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest 79: 1151-1159, 1999
28. Cayatte AJ, Rupin A, Oliver-Krasinski J, Maitland K, Sansilvestri-Morel P, Boussard MF, Wierzbicki M, Verbeuren TJ, and Cohen RA. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler Thromb Vasc Biol 21: 1577-1584, 2001
29. Chamulitrat W, Schmidt R, Tomakidi P, Stremmel W, Chunglok W, Kawahara T, and Rokutan K. Association of gp91phox homolog Nox1 with anchorage-independent growth and MAP kinase-Activation of transformed human keratinocytes. Oncogene 22: 6045-6053, 2003
30. Chan CT, Moore JP, Budzyn K, Guida E, Diep H, Vinh A, Jones ES, Widdop RE, Armitage JA, Sakkal S, Ricardo SD, Sobey CG, and Drummond GR. Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in deoxycorticosterone/salt-Treated mice. Hypertension 60: 1207-1212, 2012
31. Chan SH, Hsu KS, Huang CC, Wang LL, Ou CC, and Chan JY. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced pressor effect via activation of p38 mitogen-Activated protein kinase in the rostral ventrolateral medulla. Circ Res 97: 772-780, 2005
32. Chen XL, Zhang Q, Zhao R, and Medford RM. Superoxide, H2O2, and iron are required for TNF-Alpha-induced MCP-1 gene expression in endothelial cells: Role of Rac1 and NADPH oxidase. Am J Physiol Heart Circ Physiol 286: H1001-H1007, 2004
33. Cheng G, Cao Z, Xu X, van Meir EG, and Lambeth JD. Homologs of gp91phox: Cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 269: 131-140, 2001
34. Cheng G and Lambeth JD. NOXO1, regulation of lipid binding, localization, and activation of Nox1 by the Phox homology (PX) domain. J Biol Chem 279: 4737-4742, 2004
35. Chrissobolis S, Banfi B, Sobey CG, and Faraci FM. Role of Nox isoforms in angiotensin II-induced oxidative stress and endothelial dysfunction in brain. J Appl Physiol 113: 184-191, 2012
36. Cifuentes ME and Pagano PJ. Targeting reactive oxygen species in hypertension. Curr Opin Nephrol Hypertens 15: 179-186, 2006
37. Clempus RE, Sorescu D, Dikalova AE, Pounkova L, Jo P, Sorescu GP, Schmidt HH, Lassegue B, and Griendling KK. Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 27: 42-48, 2007
38. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, and Sorescu D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97: 900-907, 2005
39. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, and Griendling KK. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 329 (Pt 3): 653-657, 1998
40. Dekker LV, Leitges M, Altschuler G, Mistry N, McDermott A, Roes J, and Segal AW. Protein kinase C-beta contributes to NADPH oxidase activation in neutrophils. Biochem J 347 Pt 1: 285-289, 2000
41. Desouki MM, Kulawiec M, Bansal S, Das GM, and Singh KK. Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors. Cancer Biol Ther 4: 1367-1373, 2005
42. Diatchuk V, Lotan O, Koshkin V, Wikstroem P, and Pick E. Inhibition of NADPH oxidase activation by 4-(2-Aminoethyl)-benzenesulfonyl fluoride and related compounds. J Biol Chem 272: 13292-13301, 1997
43. Diebold I, Petry A, Hess J, and Gorlach A. The NADPH oxidase subunit NOX4 is a new target gene of the hypoxiainducible factor-1. Mol Biol Cell 21: 2087-2096, 2010
44. Dikalov SI, Dikalova AE, Bikineyeva AT, Schmidt HH, Harrison DG, and Griendling KK. Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med 45: 1340-1351, 2008
45. Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J, Dikalov S, San Martin A, Lyle A, Weber DS, Weiss D, Taylor WR, Schmidt HH, Owens GK, Lambeth JD, and Griendling KK. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 112: 2668-2676, 2005
46. Dikalova AE, Gongora MC, Harrison DG, Lambeth JD, Dikalov S, and Griendling KK. Upregulation of Nox1 in vascular smooth muscle leads to impaired endotheliumdependent relaxation via eNOS uncoupling. Am J Physiol Heart Circ Physiol 299: H673-H679, 2010
47. Ding H, Aljofan M, and Triggle CR. Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. J Cell Physiol 212: 682-689, 2007
48. Ding H, Hashem M, and Triggle C. Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: Changes in expression of NADPH oxidase subunits and eNOS. Eur J Pharmacol 561: 121-128, 2007
49. Ding L, Chapman A, Boyd R, and Wang HD. ERK activation contributes to regulation of spontaneous contractile tone via superoxide anion in isolated rat aorta of angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 292: H2997-H3005, 2007
50. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, and Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25: 519-525, 2005
51. Douglas G, Bendall JK, Crabtree MJ, Tatham AL, Carter EE, Hale AB, and Channon KM. Endothelial-specific Nox2 overexpression increases vascular superoxide and macrophage recruitment in ApoE(-)/(-) mice. Cardiovasc Res 94: 20-29, 2012
52. Fenyo IM, Florea IC, Raicu M, and Manea A. Tyrphostin AG490 reduces NAPDH oxidase activity and expression in the aorta of hypercholesterolemic apolipoprotein E-deficient mice. Vascul Pharmacol 54: 100-106, 2011
53. Fike CD, Slaughter JC, Kaplowitz MR, Zhang Y, and Aschner JL. Reactive oxygen species from NADPH oxidase contribute to altered pulmonary vascular responses in piglets with chronic hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 295: L881-L888, 2008
54. Fortuno A, Bidegain J, Robador PA, Hermida J, Lopez-Sagaseta J, Beloqui O, Diez J, and Zalba G. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: Potential clinical implications in hypertension. Hypertension 54: 744-750, 2009
55. Fu R, Wang Q, Guo Q, Xu J, and Wu X. XJP-1 protects endothelial cells from oxidized low-density lipoprotein-induced apoptosis by inhibiting NADPH oxidase subunit expression and modulating the PI3K/Akt/eNOS pathway. Vascul Pharmacol 58: 78-86, 2013
56. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Qt, Taylor WR, Harrison DG, De Leon H, Wilcox JN, and Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45-51, 1997
57. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, and Ley K. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med 203: 1273-1282, 2006
58. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, and Zucker IH. Superoxide mediates sympathoexcitation in heart failure: Roles of angiotensin II and NAD(P)H oxidase. Circ Res 95: 937-944, 2004
59. Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C, Heitz F, Page P, Montet X, Michalik L, Arbiser J, Ruegg C, Krause KH, and Imhof BA. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS One 6: E14665, 2011
60. Gatto GJ, Jr., Ao Z, Kearse MG, Zhou M, Morales CR, Daniels E, Bradley BT, Goserud MT, Goodman KB, Douglas SA, Harpel MR, and Johns DG. NADPH oxidasedependent and-independent mechanisms of reported inhibitors of reactive oxygen generation. J Enzyme Inhib Med Chem 28: 95-104, 2013
61. Gavazzi G, Banfi B, Deffert C, Fiette L, Schappi M, Herrmann F, and Krause KH. Decreased blood pressure in NOX1-deficient mice. FEBS Lett 580: 497-504, 2006
62. Gavazzi G, Deffert C, Trocme C, Schappi M, Herrmann FR, and Krause KH. NOX1 deficiency protects from aortic dissection in response to angiotensin II. Hypertension 50: 189-196, 2007
63. Geiszt M, Kopp JB, Varnai P, and Leto TL. Identification of Renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A 97: 8010-8014, 2000
64. Gianni D, Nicolas N, Zhang H, Der Mardirossian C, Kister J, Martinez L, Ferguson J, Roush WR, Brown SJ, Bokoch GM, Hodder P, and Rosen H. Optimization and characterization of an inhibitor for NADPH oxidase 1 (NOX-1). In: Probe Reports from the NIH Molecular Libraries Program. Bethesda, MD, 2010
65. Goettsch C, Goettsch W, Arsov A, Hofbauer LC, Bornstein SR, and Morawietz H. Long-Term cyclic strain downregulates endothelial Nox4. Antioxid Redox Signal 11: 2385-2397, 2009
66. Goettsch C, Goettsch W, Muller G, Seebach J, Schnittler HJ, and Morawietz H. Nox4 overexpression activates reactive oxygen species and p38 MAPK in human endothelial cells. Biochem Biophys Res Commun 380: 355-360, 2009
67. Gongora MC, Lob HE, Landmesser U, Guzik TJ, Martin WD, Ozumi K, Wall SM, Wilson DS, Murthy N, Gravanis M, Fukai T, and Harrison DG. Loss of extracellular superoxide dismutase leads to acute lung damage in the presence of ambient air: A potential mechanism underlying adult respiratory distress syndrome. Am J Pathol 173: 915-926, 2008
68. Gorin Y, Ricono JM, Kim NH, Bhandari B, Choudhury GG, and Abboud HE. Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am J Physiol Renal Physiol 285: F219-F229, 2003
69. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, Rodenburg RJ, Smeitink JA, Oberley L, Zhang Y, Slingerland J, Arnold RS, Lambeth JD, Cohen C, Hilenski L, Griendling K, Martinez-Diez M, Cuezva JM, and Arbiser JL. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117: 719-729, 2007
70. Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, De Haan JB, Koulis C, El-Osta A, and rews KL, Chin-Dusting JP, Touyz RM, Wingler K, Cooper ME, Schmidt HH, and Jandeleit-Dahm KA. NADPH oxidase 1 plays a key role in diabetes mellitus-Accelerated atherosclerosis. Circulation 127: 1888-1902, 2013
71. Green DE, Murphy TC, Kang BY, Kleinhenz JM, Szyndralewiez C, Page P, Sutliff RL, and Hart CM. The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. Am J Respir Cell Mol Biol 47: 718-726, 2012
72. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994
73. Gupte SA and Wolin MS. Oxidant and redox signaling in vascular oxygen sensing: Implications for systemic and pulmonary hypertension. Antioxid Redox Signal 10: 1137-1152, 2008
74. Guzik B, Chwala M, Matusik P, Ludew D, Skiba D, Wilk G, Mrowiecki W, Batko B, Cencora A, Kapelak B, Sadowski J, Korbut R, and Guzik TJ. Mechanisms of increased vascular superoxide production in human varicose veins. Pol Arch Med Wewn 121: 279-286, 2011
75. Guzik B, Sagan A, Ludew D, Mrowiecki W, Chwala M, Bujak-Gizycka B, Filip G, Grudzien G, Kapelak B, Zmudka K, Mrowiecki T, Sadowski J, Korbut R, and Guzik TJ. Mechanisms of oxidative stress in human aortic aneurysms-Association with clinical risk factors for atherosclerosis and disease severity. Int J Cardiol 2013 [Epub ahead of print]; DOI: 10.1016/j.ijcard.2013.01.278
76. Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, Hoch N, Dikalov S, Rudzinski P, Kapelak B, Sadowski J, and Harrison DG. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol 52: 1803-1809, 2008
77. Guzik TJ and Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 11: 524-533, 2006
78. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, and Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460, 2007
79. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, and Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105: 1656-1662, 2002
80. Guzik TJ, Sadowski J, Guzik B, Jopek A, Kapelak B, Przybylowski P, Wierzbicki K, Korbut R, Harrison DG, and Channon KM. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 26: 333-339, 2006
81. Guzik TJ, Sadowski J, Kapelak B, Jopek A, Rudzinski P, Pillai R, Korbut R, and Channon KM. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol 24: 1614-1620, 2004
82. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, and Channon KM. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 102: 1744-1747, 2000
83. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, and Channon KM. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res 86: E85-E90, 2000
84. Harrison DG, Gongora MC, Guzik TJ, and Widder J. Oxidative stress and hypertension. J Am Soc Hypertens 1: 30-44, 2007
85. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, and Weyand CM. Inflammation, immunity, and hypertension. Hypertension 57: 132-140, 2011
86. Helmcke I, Heumuller S, Tikkanen R, Schroder K, and Brandes RP. Identification of structural elements in Nox1 and Nox4 controlling localization and activity. Antioxid Redox Signal 11: 1279-1287, 2009
87. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K, and Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51: 211-217, 2008
88. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, and Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 24: 677-683, 2004
89. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, and Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: E14-E22, 2001
90. Hopkins ND, Stratton G, Tinken TM, Ridgers ND, Graves LE, McWhannell N, Cable NT, and Green DJ. Seasonal reduction in physical activity and flow-mediated dilation in children. Med Sci Sports Exerc 43: 232-238, 2011
91. Hsich E, Segal BH, Pagano PJ, Rey FE, Paigen B, Deleonardis J, Hoyt RF, Holland SM, and Finkel T. Vascular effects following homozygous disruption of p47(phox): An essential component of NADPH oxidase. Circulation 101: 1234-1236, 2000
92. Hwang J, Ing MH, Salazar A, Lassegue B, Griendling K, Navab M, Sevanian A, and Hsiai TK. Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: Implication for native LDL oxidation. Circ Res 93: 1225-1232, 2003
93. Infanger DW, Sharma RV, and Davisson RL. NADPH oxidases of the brain: Distribution, regulation, and function. Antioxid Redox Signal 8: 1583-1596, 2006
94. Ismail S, Sturrock A, Wu P, Cahill B, Norman K, Huecksteadt T, Sanders K, Kennedy T, and Hoidal J. NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: The role of autocrine production of transforming growth factor-{beta}1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol 296: L489-L499, 2009
95. Jansen F, Yang X, Franklin BS, Hoelscher M, Schmitz T, Bedorf J, Nickenig G, and Werner N. High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation. Cardiovasc Res 98: 94-106, 2013
96. Jaquet V, Marcoux J, Forest E, Leidal KG, McCormick S, Westermaier Y, Perozzo R, Plastre O, Fioraso-Cartier L, Diebold B, Scapozza L, Nauseef WM, Fieschi F, Krause KH, and Bedard K. NADPH oxidase (NOX) isoforms are inhibited by celastrol with a dual mode of action. Br J Pharmacol 164: 507-520, 2011
97. Jay DB, Papaharalambus CA, Seidel-Rogol B, Dikalova AE, Lassegue B, and Griendling KK. Nox5 mediates PDGF-induced proliferation in human aortic smooth muscle cells. Free Radic Biol Med 45: 329-335, 2008
98. Judkins CP, Diep H, Broughton BR, Mast AE, Hooker EU, Miller AA, Selemidis S, Dusting GJ, Sobey CG, and Drummond GR. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/-mice. Am J Physiol Heart Circ Physiol 298: H24-H32, 2010
99. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, and Brandes RP. gp91phox-containing NADPH oxidase medi-Ates endothelial dysfunction in renovascular hypertension. Circulation 109: 1795-1801, 2004
100. Kadl A, Galkina E, and Leitinger N. Induction of CCR2-dependent macrophage accumulation by oxidized phospholipids in the air-pouch model of inflammation. Arthritis Rheum 60: 1362-1371, 2009
101. Kawano M, Miyamoto K, Kaito Y, Sumimoto H, and Tamura M. Noxa1 as a moderate activator of Nox2-based NADPH oxidase. Arch Biochem Biophys 519: 1-7, 2012
102. Khatri JJ, Johnson C, Magid R, Lessner SM, Laude KM, Dikalov SI, Harrison DG, Sung HJ, Rong Y, and Galis ZS. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 109: 520-525, 2004
103. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, and LeBoeuf RC. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 20: 1529-1535, 2000
104. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, Barit D, Schwarz T, Geis C, Kraft P, Barthel K, Schuhmann MK, Herrmann AM, Meuth SG, Stoll G, Meurer S, Schrewe A, Becker L, Gailus-Durner V, Fuchs H, Klopstock T, De Angelis MH, Jandeleit-Dahm K, Shah AM, Weissmann N, and Schmidt HH. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 8: Pii:e1000479, 2010
105. Koltsova EK, Garcia Z, Chodaczek G, Landau M, McArdle S, Scott SR, von Vietinghoff S, Galkina E, Miller YI, Acton ST, and Ley K. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest 122: 3114-3126, 2012
106. Konior A, Klemenska E, Brudek M, Podolecka E, Czarnowska E, and Beresewicz A. Seasonal superoxide overproduction and endothelial activation in guinea-pig heart; seasonal oxidative stress in rats and humans. J Mol Cell Cardiol 50: 686-694, 2011
107. Kovacic HN, Irani K, and Goldschmidt-Clermont PJ. Redox regulation of human Rac1 stability by the proteasome in human aortic endothelial cells. J Biol Chem 276: 45856-45861, 2001
108. Kuroda J, Nakagawa K, Yamasaki T, Nakamura K, Takeya R, Kuribayashi F, Imajoh-Ohmi S, Igarashi K, Shibata Y, Sueishi K, and Sumimoto H. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells 10: 1139-1151, 2005
109. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, and Harrison DG. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40: 511-515, 2002
110. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, and Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201-1209, 2003
111. Lassegue B and Clempus RE. Vascular NAD(P)H oxidases: Specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285: R277-R297, 2003
112. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, and Griendling KK. Novel gp91(phox) homologues in vascular smooth muscle cells: Nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88: 888-894, 2001
113. Laude K, Cai H, Fink B, Hoch N, Weber DS, McCann L, Kojda G, Fukai T, Schmidt HH, Dikalov S, Ramasamy S, Gamez G, Griendling KK, and Harrison DG. Hemodynamic and biochemical adaptations to vascular smooth muscle overexpression of p22phox in mice. Am J Physiol Heart Circ Physiol 288: H7-H12, 2005
114. Lavigne MC, Malech HL, Holland SM, and Leto TL. Genetic demonstration of p47phox-dependent superoxide anion production in murine vascular smooth muscle cells. Circulation 104: 79-84, 2001
115. Lee MY, San Martin A, Mehta PK, Dikalova AE, Garrido AM, Datla SR, Lyons E, Krause KH, Banfi B, Lambeth JD, Lassegue B, and Griendling KK. Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation. Arterioscler Thromb Vasc Biol 29: 480-487, 2009
116. Lee YM, Kim BJ, Chun YS, So I, Choi H, Kim MS, and Park JW. NOX4 as an oxygen sensor to regulate TASK-1 activity. Cell Signal 18: 499-507, 2006
117. Li J, Stouffs M, Serrander L, Banfi B, Bettiol E, Charnay Y, Steger K, Krause KH, and Jaconi ME. The NADPH oxidase NOX4 drives cardiac differentiation: Role in regulating cardiac transcription factors and MAP kinase activation. Mol Biol Cell 17: 3978-3988, 2006
118. Li JM and Shah AM. Endothelial cell superoxide generation: Regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 287: R1014-R1030, 2004
119. Li WG, Miller FJ, Jr., Zhang HJ, Spitz DR, Oberley LW, and Weintraub NL. H(2)O(2)-induced O(2) production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. J Biol Chem 276: 29251-29256, 2001
120. Liang CF, Liu JT, Wang Y, Xu A, and Vanhoutte PM. Tolllike receptor 4 mutation protects obese mice against endothelial dysfunction by decreasing NADPH oxidase isoforms 1 and 4. Arterioscler Thromb Vasc Biol 33: 777-784, 2013
121. Libby P, Ridker PM, and Maseri A. Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002
122. Lichtman AH, Binder CJ, Tsimikas S, and Witztum JL. Adaptive immunity in atherogenesis: New insights and therapeutic approaches. J Clin Invest 123: 27-36, 2013
123. Liu J, Yang F, Yang XP, Jankowski M, and Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol 23: 776-782, 2003
124. Liu JQ, Zelko IN, Erbynn EM, Sham JS, and Folz RJ. Hypoxic pulmonary hypertension: Role of superoxide and NADPH oxidase (gp91phox). Am J Physiol Lung Cell Mol Physiol 290: L2-L10, 2006
125. Liu Y, Davidson BP, Yue Q, Belcik T, Xie A, Inaba Y, McCarty OJ, Tormoen GW, Zhao Y, Ruggeri ZM, Kaufmann BA, and Lindner JR. Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ Cardiovasc Imaging 6: 74-82, 2013
126. Lob HE, Marvar PJ, Guzik TJ, Sharma S, McCann LA, Weyand C, Gordon FJ, and Harrison DG. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension 55: 277-283, 6p following 283, 2010
127. Lob HE, Schultz D, Marvar PJ, Davisson RL, and Harrison DG. Role of the NADPH oxidases in the subfornical organ in angiotensin II-induced hypertension. Hypertension 61: 382-387, 2013
128. Lu X, Murphy TC, Nanes MS, and Hart CM. PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa} B. Am J Physiol Lung Cell Mol Physiol 299: L559-L566, 2010
129. Lyle AN, Deshpande NN, Taniyama Y, Seidel-Rogol B, Pounkova L, Du P, Papaharalambus C, Lassegue B, and Griendling KK. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res 105: 249-259, 2009
130. Madrigal-Matute J, Fernandez-Garcia CE, Gomez-Guerrero C, Lopez-Franco O, Munoz-Garcia B, Egido J, Blanco-Colio LM, and Martin-Ventura JL. HSP90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis. Cardiovasc Res 95: 116-123, 2012
131. Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS, Cheng G, Lambeth JD, and Goldstein BJ. The NAD(P)H oxidase homolog Nox4 modulates insulin-stimulated generation of H2O2 and plays an integral role in insulin signal transduction. Mol Cell Biol 24: 1844-1854, 2004
132. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, and Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 18: 69-82, 2006
133. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, Takai S, Yamanishi K, Miyazaki M, Matsubara H, and Yabe-Nishimura C. Nox1 is involved in angiotensin II-mediated hypertension: A study in Nox1-deficient mice. Circulation 112: 2677-2685, 2005
134. Miguel-Carrasco JL, Zambrano S, Blanca AJ, Mate A, and Vazquez CM. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm (Lond) 7: 21, 2010
135. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, Boullier A, Gonen A, Diehl CJ, Que X, Montano E, Shaw PX, Tsimikas S, Binder CJ, and Witztum JL. Oxidation-specific epitopes are danger-Associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 108: 235-248, 2011
136. Mittal M, Roth M, Konig P, Hofmann S, Dony E, Goyal P, Selbitz AC, Schermuly RT, Ghofrani HA, Kwapiszewska G, Kummer W, Klepetko W, Hoda MA, Fink L, Hanze J, Seeger W, Grimminger F, Schmidt HH, and Weissmann N. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res 101: 258-267, 2007
137. Mochizuki T, Furuta S, Mitsushita J, Shang WH, Ito M, Yokoo Y, Yamaura M, Ishizone S, Nakayama J, Konagai A, Hirose K, Kiyosawa K, and Kamata T. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis
138. Modlinger P, Chabrashvili T, Gill PS, Mendonca M, Harrison DG, Griendling KK, Li M, Raggio J, Wellstein A, Chen Y, Welch WJ, and Wilcox CS. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 47: 238-244, 2006
139. Moe KT, Yin NO, Naylynn TM, Khairunnisa K, Wutyi MA, Gu Y, Atan MS, Wong MC, Koh TH, and Wong P. Nox2 and Nox4 mediate tumour necrosis factor-Alpha-induced ventricular remodelling in mice. J Cell Mol Med 15: 2601-2613, 2011
140. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, and Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90: E58-E65, 2002
141. Monte M, Davel LE, and Sacerdote De Lustig E. Hydrogen peroxide is involved in lymphocyte activation mechanisms to induce angiogenesis. Eur J Cancer 33: 676-682, 1997
142. Nakane H, Miller FJ, Jr., Faraci FM, Toyoda K, and Heistad DD. Gene transfer of endothelial nitric oxide synthase reduces angiotensin II-induced endothelial dysfunction. Hypertension 35: 595-601, 2000
143. Nauseef WM. Nox enzymes in immune cells. Semin Immunopathol 30: 195-208, 2008
144. Nisbet RE, Bland JM, Kleinhenz DJ, Mitchell PO, Walp ER, Sutliff RL, and Hart CM. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol 42: 482-490, 2010
145. O'Brien KD, McDonald TO, Chait A, Allen MD, and Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 93: 672-682, 1996
146. O'Donnell BV, Tew DG, Jones OT, and England PJ. Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem J 290 (Pt 1): 41-49, 1993
147. Oliveira-Sales EB, Nishi EE, Carillo BA, Boim MA, Dolnikoff MS, Bergamaschi CT, and Campos RR. Oxidative stress in the sympathetic premotor neurons contributes to sympathetic activation in renovascular hypertension. Am J Hypertens 22: 484-492, 2009
148. Olukman M, Orhan CE, Celenk FG, and Ulker S. Apocynin restores endothelial dysfunction in streptozotocin diabetic rats through regulation of nitric oxide synthase and NADPH oxidase expressions. J Diabetes Complications 24: 415-423, 2010
149. Pagano PJ, Chanock SJ, Siwik DA, Colucci WS, and Clark JK. Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension 32: 331-337, 1998
150. Paravicini TM and Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: Clinical implications and therapeutic possibilities. Diabetes Care 31 Suppl 2: S170-S180, 2008
151. Park HS, Chun JN, Jung HY, Choi C, and Bae YS. Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. Cardiovasc Res 72: 447-455, 2006
152. Pedruzzi E, Guichard C, Ollivier V, Driss F, Fay M, Prunet C, Marie JC, Pouzet C, Samadi M, Elbim C, O'Dowd Y, Bens M, Vandewalle A, Gougerot-Pocidalo MA, Lizard G, and Ogier-Denis E. NAD(P)H oxidase Nox-4 mediates 7-ketocholesterol-induced endoplasmic reticulum stress and apoptosis in human aortic smooth muscle cells. Mol Cell Biol 24: 10703-10717, 2004
153. Pendyala S, Usatyuk PV, Gorshkova IA, Garcia JG, and Natarajan V. Regulation of NADPH oxidase in vascular endothelium: The role of phospholipases, protein kinases, and cytoskeletal proteins. Antioxid Redox Signal 11: 841-860, 2009
154. Peterson JR, Burmeister MA, Tian X, Zhou Y, Guruju MR, Stupinski JA, Sharma RV, and Davisson RL. Genetic silencing of Nox2 and Nox4 reveals differential roles of these NADPH oxidase homologues in the vasopressor and dipsogenic effects of brain angiotensin II. Hypertension 54: 1106-1114, 2009
155. Purushothaman D and Sarin A. Cytokine-dependent regulation of NADPH oxidase activity and the consequences for activated T cell homeostasis. J Exp Med 206: 1515-1523, 2009
156. Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Zuodar G, and Ceriello A. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: The distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 183: 259-267, 2005
157. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, and Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923, 1996
158. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, Anilkumar N, Ouattara A, Cave AC, Walker SJ, Grieve DJ, Charles RL, Eaton P, Brewer AC, and Shah AM. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 31: 1368-1376, 2011
159. Ray R and Shah AM. NADPH oxidase and endothelial cell function. Clin Sci (Lond) 109: 217-226, 2005
160. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, and Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res 89: 408-414, 2001
161. Rey FE, Li XC, Carretero OA, Garvin JL, and Pagano PJ. Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation: Role of gp91(phox). Circulation 106: 2497-2502, 2002
162. Rius C, Piqueras L, Gonzalez-Navarro H, Albertos F, Company C, Lopez-Gines C, Ludwig A, Blanes JI, Morcillo EJ, and Sanz MJ. Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II. Arterioscler Thromb Vasc Biol 33: 96-104, 2013
163. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, and Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: Antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 104: 1767-1772, 2001
164. Ryszawa N, Kawczynska-Drozdz A, Pryjma J, Czesnikiewicz-Guzik M, Adamek-Guzik T, Naruszewicz M, Korbut R, and Guzik TJ. Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis. J Physiol Pharmacol 57: 611-626, 2006
165. Schramm A, Matusik P, Osmenda G, and Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol 56: 216-231, 2012
166. Schroder K, Wandzioch K, Helmcke I, and Brandes RP. Nox4 acts as a switch between differentiation and proliferation in preadipocytes. Arterioscler Thromb Vasc Biol 29: 239-245, 2009
167. Schroder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luedike P, Michaelis UR, Weissmann N, Dimmeler S, Shah AM, and Brandes RP. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 110: 1217-1225, 2012
168. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, and Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: Upstream mediators. Circ Res 91: 406-413, 2002
169. Shinozaki K, Ayajiki K, Nishio Y, Sugaya T, Kashiwagi A, and Okamura T. Evidence for a causal role of the reninangiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 43: 255-262, 2004
170. Simpson CS and Morris BJ. Regulation of neuronal cell adhesion molecule expression by NF-kappa B. J Biol Chem 275: 16879-16884, 2000
171. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, and Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105: 1429-1435, 2002
172. Stielow C, Catar RA, Muller G, Wingler K, Scheurer P, Schmidt HH, and Morawietz H. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun 344: 200-205, 2006
173. Stolk J, Hiltermann TJ, Dijkman JH, and Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 11: 95-102, 1994
174. Sturrock A, Cahill B, Norman K, Huecksteadt TP, Hill K, Sanders K, Karwande SV, Stringham JC, Bull DA, Gleich M, Kennedy TP, and Hoidal JR. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 290: L661-L673, 2006
175. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, and Lambeth JD. Cell transformation by the superoxide-generating oxidase Mox1. Nature 401: 79-82, 1999
176. Szocs K, Lassegue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, Quinn MT, Lambeth JD, and Griendling KK. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 22: 21-27, 2002
177. Takac I, Schroder K, and Brandes RP. The nox family of NADPH oxidases: Friend or foe of the vascular system?. Curr Hypertens Rep 14: 70-78, 2012
178. Takac I, Schroder K, Zhang L, Lardy B, Anilkumar N, Lambeth JD, Shah AM, Morel F, and Brandes RP. The Eloop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J Biol Chem 286: 13304-13313, 2011
179. Takai S, Jin D, Kawashima H, Kimura M, Shiraishi-Tateishi A, Tanaka T, Kakutani S, Tanaka K, Kiso Y, and Miyazaki M. Anti-Atherosclerotic effects of dihomo-gamma-linolenic acid in ApoE-deficient mice. J Atheroscler Thromb 16: 480-489, 2009
180. Tazzeo T, Worek F, and Janssen L. The NADPH oxidase inhibitor diphenyleneiodonium is also a potent inhibitor of cholinesterases and the internal Ca(2 + ) pump. Br J Pharmacol 158: 790-796, 2009
181. ten Freyhaus H, Huntgeburth M, Wingler K, Schnitker J, Baumer AT, Vantler M, Bekhite MM, Wartenberg M, Sauer H, and Rosenkranz S. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 71: 331-341, 2006
182. Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev N, and Alexander RW. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation 111: 2347-2355, 2005
183. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, and Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-Type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: Regulation by angiotensin II. Circ Res 90: 1205-1213, 2002
184. Touyz RM, Mercure C, He Y, Javeshghani D, Yao G, Callera GE, Yogi A, Lochard N, and Reudelhuber TL. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension 45: 530-537, 2005
185. Ullevig S, Zhao Q, Lee CF, Seok Kim H, Zamora D, and Asmis R. NADPH oxidase 4 mediates monocyte priming and accelerated chemotaxis induced by metabolic stress. Arterioscler Thromb Vasc Biol 32: 415-426, 2012
186. Urao N, Inomata H, Razvi M, Kim HW, Wary K, McKinney R, Fukai T, and Ushio-Fukai M. Role of nox2-based NADPH oxidase in bone marrow and progenitor cell function involved in neovascularization induced by hindlimb ischemia. Circ Res 103: 212-220, 2008
187. Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, Quinn MT, Pagano PJ, Johnson C, and Alexander RW. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 91: 1160-1167, 2002
188. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, and Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271: 23317-23321, 1996
189. Van Buul JD, Fernandez-Borja M, Anthony EC, and Hordijk PL. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid Redox Signal 7: 308-317, 2005
190. Verbeuren TJ, Bouskela E, Cohen RA, and Vanhoutte PM. Regulation of adhesion molecules: A new target for the treatment of chronic venous insufficiency. Microcirculation 7: S41-S48, 2000
191. Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, Weyand CM, Harrison DG, and Guzik TJ. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation 122: 2529-2537, 2010
192. Violi F, Pignatelli P, Pignata C, Plebani A, Rossi P, Sanguigni V, Carnevale R, Soresina A, Finocchi A, Cirillo E, Catasca E, Angelico F, and Loffredo L. Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress. Arterioscler Thromb Vasc Biol 33: 406-412, 2013
193. Violi F, Sanguigni V, Carnevale R, Plebani A, Rossi P, Finocchi A, Pignata C, De Mattia D, Martire B, Pietrogrande MC, Martino S, Gambineri E, Soresina AR, Pignatelli P, Martino F, Basili S, and Loffredo L. Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: Results of a multicenter study. Circulation 120: 1616-1622, 2009
194. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, and Cohen RA. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 88: 947-953, 2001
195. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, and Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280: E685-E694, 2001
196. Weber DS, Rocic P, Mellis AM, Laude K, Lyle AN, Harrison DG, and Griendling KK. Angiotensin II-induced hypertrophy is potentiated in mice overexpressing p22phox in vascular smooth muscle. Am J Physiol Heart Circ Physiol 288: H37-H42, 2005
197. Wei Y, Whaley-Connell AT, Chen K, Habibi J, Uptergrove GM, Clark SE, Stump CS, Ferrario CM, and Sowers JR. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 50: 384-391, 2007
198. West N, Guzik T, Black E, and Channon K. Enhanced superoxide production in experimental venous bypass graft intimal hyperplasia: Role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 21: 189-194, 2001
199. Wind S, Beuerlein K, Armitage ME, Taye A, Kumar AH, Janowitz D, Neff C, Shah AM, Wingler K, and Schmidt HH. Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension 56: 490-497, 2010
200. Wind S, Beuerlein K, Eucker T, Muller H, Scheurer P, Armitage ME, Ho H, Schmidt HH, and Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 161: 885-898, 2010
201. Wu F, Han M, and Wilson JX. Tripterine prevents endothelial barrier dysfunction by inhibiting endogenous peroxynitrite formation. Br J Pharmacol 157: 1014-1023, 2009
202. Wung BS, Cheng JJ, Hsieh HJ, Shyy YJ, and Wang DL. Cyclic strain-induced monocyte chemotactic protein-1 gene expression in endothelial cells involves reactive oxygen species activation of activator protein 1. Circ Res 81: 1-7, 1997
203. Xue B, Beltz TG, Johnson RF, Guo F, Hay M, and Johnson AK. PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate aldosterone/NaCl-induced hypertension in mice. Am J Physiol Heart Circ Physiol 302: H733-H741, 2012
204. Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Nako H, Ogawa H, and Kim-Mitsuyama S. Benidipine, a dihydropyridine L-Type/T-Type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats. J Hypertens 28: 1321-1329, 2010
205. Yogi A, Mercure C, Touyz J, Callera GE, Montezano AC, Aranha AB, Tostes RC, Reudelhuber T, and Touyz RM. Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension 51: 500-506, 2008
206. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, Taylor WR, and Griendling KK. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin IIinduced vascular hypertrophy. Hypertension 32: 488-495, 1998
207. Zhang L, Zalewski A, Liu Y, Mazurek T, Cowan S, Martin JL, Hofmann SM, Vlassara H, and Shi Y. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 108: 472-478, 2003
208. Zhou MS, Hernandez Schulman I, Pagano PJ, Jaimes EA, and Raij L. Reduced NAD(P)H oxidase in low renin hypertension: Link among angiotensin II, atherogenesis, and blood pressure. Hypertension 47: 81-86, 2006
209. Zimmerman MC, Dunlay RP, Lazartigues E, Zhang Y, Sharma RV, Engelhardt JF, and Davisson RL. Requirement for Rac1-dependent NADPH oxidase in the cardiovascular and dipsogenic actions of angiotensin II in the brain. Circ Res 95: 532-539, 2004
210. Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR, and Davisson RL. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res 91: 1038-1045, 2002
211. Zimmerman MC, Lazartigues E, Sharma RV, and Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 95: 210-216, 2004